IGF-1 LR3
FitnessAlso known as: Long R3 IGF-1, Insulin-Like Growth Factor-1 LR3, Long Arg3 IGF-I
Limited EvidenceWhat is IGF-1 LR3?
A modified analog of insulin-like growth factor-1 (IGF-1) engineered to have an extended half-life and reduced binding to IGF-binding proteins. Popular in bodybuilding and performance communities as the "downstream" complement to GH-stimulating peptides like CJC-1295 and Ipamorelin. Not FDA-approved, banned by WADA, and carries significant metabolic risks without medical oversight.
How it works
Native IGF-1 is rapidly sequestered by IGF-binding proteins (IGFBPs), especially IGFBP-3, limiting its activity window to 12–15 hours. LR3 is modified with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension that dramatically reduces IGFBP binding affinity — extending half-life to approximately 20–30 hours and increasing free bioavailability. Once free, IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) and activates the PI3K–Akt–mTOR pathway (protein synthesis, cell survival) and MAPK pathway (cellular proliferation and differentiation), including activation of muscle satellite cells.
What marketers claim
- ▸builds muscle beyond genetic limits
- ▸20–40% muscle mass increase guaranteed
- ▸completely safe because it's natural
- ▸the secret to elite athletic performance
What evidence supports
- ✓IGF-1 LR3 reduces binding to IGFBPs compared to native IGF-1 — well established in biochemical and animal studies
- ✓activates mTOR and satellite cell pathways in skeletal muscle — preclinical evidence is robust
- ✓native IGF-1 is FDA-approved for severe primary IGF-1 deficiency (Laron syndrome) under the brand Increlex, establishing the target's clinical validity
- ✓animal studies show LR3 variant preserves lean mass in catabolic states and increases muscle fiber number (hyperplasia)
- ✓long-term human clinical trials for IGF-1 LR3 specifically do not currently exist
Research evidence
Key studies on IGF-1 LR3, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Insulin-like growth factor-I variants are anabolic in dexamethasone-treated rats but not in protein-malnourished rats
Finding: Long R3 IGF-I produced significantly greater muscle mass preservation than native IGF-1 in catabolic (dexamethasone-treated) rats, attributed to its reduced IGFBP binding and extended activity window.
Limitation: Rat model of steroid-induced catabolism — does not directly translate to healthy human muscle-building use cases. Dosing and delivery are not comparable to human protocols.
Cellular actions of the insulin-like growth factor binding proteins
Finding: Comprehensive review establishing that IGFBP-3 sequesters 70–80% of circulating IGF-1 in normal physiology. LR3 modification reduces IGFBP-3 affinity by ~2,000-fold, explaining the extended half-life and bioavailability of the LR3 variant.
Limitation: Review paper synthesizing existing data, not a clinical trial. Does not assess in vivo effects of IGF-1 LR3 in humans.
Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity (Laron syndrome)
Finding: Native recombinant IGF-1 (Increlex) safely improved height velocity and body composition in children with severe IGF-1 deficiency over 12 months. Establishes clinical proof-of-concept for the IGF-1 axis target — but uses native IGF-1 in a deficiency state, not LR3 in healthy adults.
Limitation: Pediatric disease population with severe IGF-1 deficiency. Cannot be extrapolated to supraphysiologic LR3 dosing in healthy adults pursuing performance or anti-aging goals.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Days 1–3
Due to the 20–30 hour half-life, IGF-1 LR3 accumulates with each dose. Users in experimental contexts report changes in muscle fullness and pump within the first few days. Blood glucose monitoring is most critical in this window.
Week 1–4
Anecdotal reports of enhanced recovery and muscle volumization. No controlled human timeline exists — all established timelines come from animal models or anecdotal community reports.
Month 2–4
Animal models suggest lean mass changes and satellite cell activation become measurable over this period with continued dosing. Human equivalent timelines are extrapolated, not validated.
Safety notes & concerns
Full safety guide →- ⚠IGF-1 LR3 is not FDA-approved for any indication — research chemical only
- ⚠banned by WADA — disqualifying for any competitive athlete subject to drug testing
- ⚠IGF-1 pathway is strongly implicated in cancer cell growth and proliferation — elevated IGF-1 is associated with increased risk of colorectal, breast, and prostate cancers in observational data
- ⚠insulin-like activity can cause hypoglycemia, especially when injected near meals
- ⚠no human safety data for the LR3 modification specifically — long-term effects are unknown
- ⚠unregulated sourcing means purity and dosing are unverified without third-party testing
- ⚠half-life of ~20–30 hours makes dosing corrections difficult if adverse effects emerge
Pairs well with
Use caution with
Frequently asked questions
What is the difference between IGF-1 LR3 and regular IGF-1?
The LR3 modification adds 13 amino acids to the N-terminus and substitutes arginine at position 3. This dramatically reduces binding to IGF-binding proteins (especially IGFBP-3), which normally sequester native IGF-1. The result is a much longer half-life (~20–30 hours vs 12–15 hours for native IGF-1) and higher free circulating activity. The FDA-approved native IGF-1 (Increlex) is used for Laron syndrome — LR3 is a research compound without approval.
Is IGF-1 LR3 the same as HGH?
No. HGH (growth hormone) is the upstream signal; IGF-1 LR3 is one of its downstream mediators. When you inject GH, the liver produces IGF-1. When you inject IGF-1 LR3, you bypass the GH step entirely and act directly at the tissue level. They have different receptor targets, different risk profiles, and different effects on blood glucose.
Can IGF-1 cause cancer?
This is a legitimate concern. IGF-1 is a known mitogenic and anti-apoptotic signal — it promotes cell growth and survival. Epidemiological studies have associated higher natural IGF-1 levels with increased risk of colorectal, breast, and prostate cancers. Whether the modest, cycling use of IGF-1 LR3 meaningfully elevates this risk in healthy adults is unknown, but the theoretical concern is not dismissed by serious researchers. Anyone with a personal or family history of these cancers should avoid IGF-1 supplementation.
How does IGF-1 LR3 fit into a CJC-1295 + Ipamorelin stack?
CJC-1295 and Ipamorelin stimulate the pituitary to release GH, which then causes the liver to produce IGF-1. Adding exogenous IGF-1 LR3 bypasses this step and acts directly on tissues. Some users add it to extend and amplify the anabolic signaling cascade. However, this multi-compound approach creates compounding risks and is well beyond what any clinical evidence supports.
Related fitness peptides
experimental recovery protocols under medical supervision
those exploring growth hormone optimization under medical supervision
those exploring GH optimization under medical supervision
understanding GH secretagogue research — use under medical supervision only
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with IGF-1 LR3
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.